Several immunotherapies have been successfully applied to multiple cancers since the testing of PD-L1 and therapies targeting PD-1 or programmed cell death ligand 1 (PD-L1) inhibitors have become a standard of care in lung cancer and renal cell carcinoma [17]. Here, CD274 is linked to lung carcinoma.